Free Trial
NASDAQ:ACIU

AC Immune Q1 2025 Earnings Report

AC Immune logo
$1.72 +0.05 (+2.99%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.70 -0.02 (-1.16%)
As of 05/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AC Immune EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.22
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

AC Immune Revenue Results

Actual Revenue
$1.12 million
Expected Revenue
$1.99 million
Beat/Miss
Missed by -$872.00 thousand
YoY Revenue Growth
N/A

AC Immune Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
9:30AM ET

Conference Call Resources

AC Immune Earnings Headlines

Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
See More AC Immune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AC Immune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AC Immune and other key companies, straight to your email.

About AC Immune

AC Immune (NASDAQ:ACIU), a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

View AC Immune Profile

More Earnings Resources from MarketBeat